IP Verse

Molecules And Methods For Modulating Low-Density-Lipoprotein Receptor-Related Protein 6 (Lrp6)

Patent No. EP2567709 (titled "Molecules And Methods For Modulating Low-Density-Lipoprotein Receptor-Related Protein 6 (Lrp6)") was filed by Novartis on Oct 31, 2008. The application was issued on Dec 27, 2017.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
MERCKSep 27, 2018-
MERCK PATENTSep 27, 2018-
BOEHRINGER INGELHEIM RCVSep 25, 2018D YOUNG
BOEHRINGER INGELHEIMSep 25, 2018D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2567709

NOVARTIS
Application Number
EP12188230A
Filing Date
Oct 31, 2008
Status
Granted And Under Opposition
Nov 24, 2017
Publication Date
Dec 27, 2017
External Links
Slate, Register , Google Patents